Paulette Denise Chandler, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholecalciferol | 6 | 2021 | 536 | 1.280 |
Why?
|
| Vitamin D | 6 | 2018 | 3222 | 1.200 |
Why?
|
| Vitamins | 5 | 2020 | 1622 | 1.020 |
Why?
|
| Vitamin D Deficiency | 6 | 2020 | 1342 | 0.950 |
Why?
|
| Dietary Supplements | 9 | 2021 | 3292 | 0.730 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2018 | 129 | 0.580 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2018 | 167 | 0.560 |
Why?
|
| Colorectal Neoplasms | 6 | 2022 | 6773 | 0.530 |
Why?
|
| Hydrochlorothiazide | 1 | 2014 | 98 | 0.470 |
Why?
|
| C-Peptide | 1 | 2015 | 420 | 0.460 |
Why?
|
| Minority Groups | 1 | 2021 | 1222 | 0.460 |
Why?
|
| Polysaccharides | 2 | 2016 | 1058 | 0.440 |
Why?
|
| Kallikreins | 1 | 2014 | 256 | 0.430 |
Why?
|
| Women's Health | 4 | 2018 | 2033 | 0.430 |
Why?
|
| Neoplasms | 9 | 2021 | 21675 | 0.430 |
Why?
|
| Inflammation Mediators | 3 | 2018 | 1888 | 0.420 |
Why?
|
| Glycoproteins | 2 | 2016 | 2266 | 0.400 |
Why?
|
| Hypercalcemia | 1 | 2014 | 409 | 0.390 |
Why?
|
| Adiponectin | 2 | 2018 | 1101 | 0.360 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 4848 | 0.360 |
Why?
|
| Appendiceal Neoplasms | 1 | 2020 | 146 | 0.320 |
Why?
|
| Adiposity | 2 | 2021 | 1806 | 0.290 |
Why?
|
| Lipids | 2 | 2016 | 3307 | 0.260 |
Why?
|
| Double-Blind Method | 8 | 2021 | 12020 | 0.260 |
Why?
|
| Biomedical Research | 1 | 2021 | 3308 | 0.260 |
Why?
|
| Coronary Disease | 1 | 2020 | 6078 | 0.260 |
Why?
|
| Calcium | 2 | 2015 | 5755 | 0.250 |
Why?
|
| Inflammation | 5 | 2019 | 10629 | 0.250 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 2471 | 0.240 |
Why?
|
| Hypertension | 2 | 2021 | 8480 | 0.220 |
Why?
|
| Middle Aged | 24 | 2021 | 213241 | 0.220 |
Why?
|
| Plants, Edible | 1 | 2021 | 30 | 0.200 |
Why?
|
| Fats | 1 | 2020 | 102 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2022 | 15518 | 0.170 |
Why?
|
| Risk Factors | 11 | 2022 | 72252 | 0.170 |
Why?
|
| Obesity | 6 | 2021 | 12744 | 0.160 |
Why?
|
| Acute-Phase Proteins | 2 | 2016 | 262 | 0.160 |
Why?
|
| Feeding Behavior | 2 | 2021 | 3187 | 0.160 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2020 | 251 | 0.160 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 12354 | 0.150 |
Why?
|
| Female | 22 | 2022 | 380020 | 0.150 |
Why?
|
| Diet Surveys | 1 | 2021 | 1173 | 0.140 |
Why?
|
| Aged | 15 | 2021 | 163178 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2018 | 9944 | 0.140 |
Why?
|
| Acetylgalactosamine | 1 | 2016 | 37 | 0.140 |
Why?
|
| Apolipoprotein B-100 | 1 | 2016 | 148 | 0.130 |
Why?
|
| Apolipoprotein A-I | 1 | 2016 | 281 | 0.130 |
Why?
|
| Vegetables | 1 | 2020 | 1181 | 0.120 |
Why?
|
| Humans | 31 | 2022 | 743811 | 0.120 |
Why?
|
| Acetylglucosamine | 1 | 2016 | 191 | 0.120 |
Why?
|
| Metabolomics | 2 | 2022 | 1487 | 0.120 |
Why?
|
| Incidence | 3 | 2018 | 20948 | 0.120 |
Why?
|
| United States | 9 | 2021 | 69859 | 0.120 |
Why?
|
| Odds Ratio | 2 | 2018 | 9848 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2016 | 21733 | 0.110 |
Why?
|
| C-Reactive Protein | 4 | 2018 | 3778 | 0.110 |
Why?
|
| Parathyroid Hormone | 1 | 2020 | 1800 | 0.110 |
Why?
|
| Calcifediol | 1 | 2013 | 166 | 0.110 |
Why?
|
| Overweight | 2 | 2021 | 2371 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2018 | 53250 | 0.110 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2018 | 967 | 0.100 |
Why?
|
| Body Mass Index | 6 | 2021 | 12718 | 0.100 |
Why?
|
| Male | 16 | 2021 | 349776 | 0.100 |
Why?
|
| Body Composition | 1 | 2021 | 2401 | 0.100 |
Why?
|
| Follow-Up Studies | 6 | 2022 | 39001 | 0.100 |
Why?
|
| Obesity, Morbid | 1 | 2021 | 1213 | 0.090 |
Why?
|
| Diuretics | 1 | 2014 | 591 | 0.090 |
Why?
|
| Gene Frequency | 1 | 2018 | 3585 | 0.090 |
Why?
|
| Diet | 2 | 2019 | 7930 | 0.090 |
Why?
|
| Adult | 11 | 2021 | 213889 | 0.090 |
Why?
|
| Survival Rate | 2 | 2020 | 12786 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 1813 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 1125 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2020 | 3082 | 0.080 |
Why?
|
| Placebos | 1 | 2013 | 1674 | 0.080 |
Why?
|
| Prevalence | 3 | 2021 | 15211 | 0.080 |
Why?
|
| Postmenopause | 1 | 2018 | 2458 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 10940 | 0.080 |
Why?
|
| Triglycerides | 1 | 2016 | 2453 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 2200 | 0.080 |
Why?
|
| Linear Models | 1 | 2018 | 5952 | 0.070 |
Why?
|
| Mitochondria | 1 | 2020 | 3513 | 0.070 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 768 | 0.070 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 2354 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 3921 | 0.070 |
Why?
|
| Palliative Care | 1 | 2021 | 3490 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2022 | 4556 | 0.070 |
Why?
|
| Comorbidity | 1 | 2020 | 10380 | 0.070 |
Why?
|
| Prognosis | 2 | 2016 | 29052 | 0.060 |
Why?
|
| Logistic Models | 2 | 2022 | 13404 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 25032 | 0.060 |
Why?
|
| Mortality | 1 | 2016 | 2862 | 0.060 |
Why?
|
| Body Weight | 1 | 2015 | 4670 | 0.060 |
Why?
|
| Disease Progression | 1 | 2020 | 13273 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 6487 | 0.060 |
Why?
|
| Cardiovascular Diseases | 4 | 2021 | 15142 | 0.060 |
Why?
|
| Poultry | 1 | 2022 | 82 | 0.050 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 20827 | 0.050 |
Why?
|
| Young Adult | 3 | 2021 | 56392 | 0.050 |
Why?
|
| Diet, Vegetarian | 1 | 2022 | 174 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 11036 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2022 | 17439 | 0.050 |
Why?
|
| Phenotype | 1 | 2018 | 16361 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2021 | 40545 | 0.040 |
Why?
|
| Leucine | 1 | 2020 | 559 | 0.040 |
Why?
|
| Adolescent | 3 | 2021 | 85729 | 0.040 |
Why?
|
| Age Factors | 2 | 2020 | 18355 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 975 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 40038 | 0.040 |
Why?
|
| Nigeria | 1 | 2020 | 733 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2013 | 8551 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2018 | 264 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 2019 | 723 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2018 | 357 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 1156 | 0.030 |
Why?
|
| SEER Program | 1 | 2020 | 1507 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2022 | 1195 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2018 | 894 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2021 | 9139 | 0.030 |
Why?
|
| Health Education | 1 | 2021 | 1056 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2018 | 1159 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2013 | 105 | 0.030 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2016 | 506 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2013 | 426 | 0.030 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2021 | 1344 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 13112 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2013 | 420 | 0.020 |
Why?
|
| Celiac Plexus | 1 | 1990 | 26 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2016 | 1125 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 3617 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2018 | 3208 | 0.020 |
Why?
|
| Bone Density | 1 | 2021 | 3460 | 0.020 |
Why?
|
| Seasons | 1 | 2013 | 1493 | 0.020 |
Why?
|
| Genotype | 1 | 2022 | 12944 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2020 | 3863 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 4422 | 0.020 |
Why?
|
| Health Behavior | 1 | 2018 | 2634 | 0.020 |
Why?
|
| Cause of Death | 1 | 2016 | 3580 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 3912 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6539 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 12243 | 0.020 |
Why?
|
| Nerve Block | 1 | 1990 | 644 | 0.010 |
Why?
|
| Risk | 1 | 2016 | 9677 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 12259 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 5264 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 57744 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 3255 | 0.010 |
Why?
|
| Boston | 1 | 2013 | 9310 | 0.010 |
Why?
|
| Algorithms | 1 | 2021 | 13869 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2021 | 77410 | 0.010 |
Why?
|
| Massachusetts | 1 | 2013 | 8660 | 0.010 |
Why?
|
| Animals | 2 | 2022 | 168660 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1990 | 2217 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 19894 | 0.010 |
Why?
|
| Pain | 1 | 1990 | 4987 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1990 | 4251 | 0.010 |
Why?
|
| Iohexol | 1 | 1990 | 196 | 0.010 |
Why?
|
| Bupivacaine | 1 | 1990 | 411 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2013 | 63042 | 0.000 |
Why?
|
| Ethanol | 1 | 1990 | 1343 | 0.000 |
Why?
|
| Radiography, Interventional | 1 | 1990 | 1095 | 0.000 |
Why?
|
| Terminal Care | 1 | 1990 | 1694 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1990 | 40964 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1990 | 20121 | 0.000 |
Why?
|